215610-30-3

Basic information

• Product Name: 1H-Pyrazole, 3-methoxy-
• CAS NO: 215610-30-3
• Molecular Formula: C4H6N2O
• Molecular Weight: 98.1044
• Mol File: 215610-30-3.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazole, 3-methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole, 3-methoxy-(215610-30-3)
• EPA Substance Registry System: 1H-Pyrazole, 3-methoxy-(215610-30-3)

Safety Data

• Hazardous Substances Data: 215610-30-3(Hazardous Substances Data)

Usage

General Description

1H-Pyrazole, 3-methoxy- is a chemical compound with the molecular formula C4H6N2O. It is a derivative of pyrazole, a five-membered ring with two nitrogen atoms at opposite positions. The presence of a methoxy group (-OCH3) on the third position of the pyrazole ring distinguishes this compound. 1H-Pyrazole, 3-methoxy- is used in various research and industrial applications, including pharmaceuticals, agrochemicals, and materials science. Its chemical structure and properties make it suitable for use as a building block in the synthesis of more complex organic molecules. Additionally, it has potential biological and pharmacological activities, which make it a subject of interest for researchers in the fields of medicinal chemistry and drug development.

Upstream product

• 852471-15-9 1-acetyl-1,2-dihydro-3H-pyrazol-3-one 
• 77-78-1 dimethyl sulfate 
• 34846-90-7 methyl 3-methoxyprop-2-enoate 
• 1361329-17-0 methyl 3-methoxy-1H-pyrazole-4-carboxylate 
• 1146950-69-7 tert-butyl 4-(4-bromo-3-methoxy-pyrazol-1-yl)piperidine-1-carboxylate 
• 186581-53-3 diazomethane 
• 137-45-1 1,2-dihydropyrazol-3-one 

Downstream Products

• 1350325-05-1 3-methoxy-4-iodopyrazole 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol "APLNR"). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.

MACROCYCLIC KINASE INHIBITORS

Compounds of Formula (I): wherein variables are defined herein, and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers for which FAK inhibition is beneficial.

Fused Bicyclic Kinase Inhibitors

Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.